|Bid||114.40 x 800|
|Ask||115.20 x 800|
|Day's Range||112.14 - 120.30|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||226.85|
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
CARLSBAD, Calif., Oct. 09, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and.
Justin Gover became the CEO of GW Pharmaceuticals plc (NASDAQ:GWPH) in 1999. This report will, first, examine the CEO...
Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.
Marijuana stocks have reversed recent losses as report finds that Americans favor decriminalizing all drugs. Thus, investing in cannabis stocks for the moment won't be a bad proposition.
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
GW Pharmaceuticals has announced the European Commission's approval of EPIDYOLEX. This will mark its entry into all European countries, including the UK.
CARLSBAD, Calif., Sept. 24, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in.
GW Pharmaceuticals (GWPH) wins EU approval for Epidyolex as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged two years and above.
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.